Zoetis Inc. Class A (ZTS) is listed on NYSE in Pharmaceutical Stocks. It is $77.31, +3.05%, with a $31.9B market cap. RSI is 53.6, neutral. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 53.6 Neutral
Market Cap $31.9B
Volume 2.5M
Fundamentals — 10-Q Q2 2026
Revenue $4.7B
Net Income $1.3B
EPS $3.08
Gross Margin 72.2%
Net Margin 27.3%
Debt / Equity 2.9x
P/E Ratio 25.1x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Damelio Frank A | Director | Buy | 6,650 | $75.39 | $501,344 | 2026 May 13 |
| Bisaro Paul | Director | Buy | 2,000 | $75.88 | $151,750 | 2026 May 13 |
| McCallister Michael B | Director | Buy | 3,000 | $77.76 | $233,273 | 2026 May 11 |
| Lagano Roxanne | Executive Vice President | Sell | 652 | $170.00 | $110,840 | 2025 Jun 3 |
| Reed Willie M | Director | Sell | 1,210 | $166.14 | $201,029 | 2025 Mar 11 |
| Lagano Roxanne | Executive Vice President | Sell | 326 | $170.00 | $55,420 | 2025 Mar 10 |
| Peck Kristin C | Chief Executive Officer | Sell | 382 | $156.68 | $59,852 | 2025 Feb 19 |
| Lagano Roxanne | Executive Vice President | Sell | 326 | $171.18 | $55,805 | 2025 Feb 11 |
| Polzer Robert J | Executive Vice President | Sell | 3,477 | $177.46 | $617,028 | 2024 Nov 25 |
| Lagano Roxanne | Executive Vice President | Sell | 923 | $151.17 | $139,530 | 2024 Apr 18 |
| Lagano Roxanne | Executive Vice President | Sell | 923 | $173.33 | $159,984 | 2024 Mar 18 |
| Reed Willie M | Director | Sell | 1,370 | $182.68 | $250,272 | 2024 Mar 11 |
| Peck Kristin C | Chief Executive Officer | Sell | 13,000 | $187.20 | $2.4M | 2024 Feb 20 |
| Lagano Roxanne | Executive Vice President | Sell | 923 | $187.30 | $172,878 | 2024 Feb 20 |
| Lagano Roxanne | Executive Vice President | Sell | 3,211 | $188.09 | $603,957 | 2024 Feb 13 |
| Lagano Roxanne | Executive Vice President | Sell | 923 | $191.43 | $176,690 | 2024 Jan 18 |
| Lagano Roxanne | Executive Vice President | Sell | 923 | $198.14 | $182,883 | 2023 Dec 18 |
| Lagano Roxanne | Executive Vice President | Sell | 2,500 | $200.00 | $500,000 | 2023 Dec 14 |
| Peck Kristin C | Chief Executive Officer | Sell | 13,000 | $176.84 | $2.3M | 2023 Nov 21 |
| Lagano Roxanne | Executive Vice President | Sell | 923 | $177.46 | $163,796 | 2023 Nov 17 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $236.99 | 45.2 | $31.7B |
| | $66.58 | 60.7 | $136.0B |
| | $515.52 | 46.7 | $22.1B |
| | $153.79 | 49.7 | -- |
Take ZTS further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put ZTS in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Zoetis Inc. Class A next reports.
Set alerts on ZTS
Get notified when Zoetis Inc. Class A hits your price targets or technical conditions are met.
Get Started Free